基于循证的伊布替尼不良反应及药学监护

doi:10.19803/j.1672-8629.2022.07.26

摘要/Abstract

摘要： 伊布替尼是首个小分子布鲁顿酪氨酸激酶（BTK）抑制剂靶向药,主要用于B细胞恶性肿瘤。随着国内外相关研究不断增加,越来越多伊布替尼的不良反应被发现,如出血、心房颤动、高血压、感染、腹泻、关节痛/肌痛、皮肤毒性、血液学毒性等。在治疗中,伊布替尼所的不良反应常属于1~2级,少见严重不良反应。通过全面检索伊布替尼相关常见和罕见不良反应的文献,归纳总结其不良反应类型及发生率,探讨预防、处理的措施和药学监护方法,以期为临床工作提供循证依据,最大程度地减少不良反应发生。

关键词: 伊布替尼, 药品不良反应, 药学监护, 循证

Abstract: Ibrutinib, a small molecule BTK inhibitor, is the first targeted drug mainly used for B cell malignant tumors. With the increase of related research at home and abroad, more and more adverse reactions induced by ibrutinib have been discovered, such as bleeding, atrial fibrillation, hypertension, infection, diarrhea, arthralgia/myalgia, skin toxicity, and hematological toxicity. Ibrutinib has been associated with an increased risk of grade 1 ~ 2 toxicities. Serious adverse events are rare. Based on literature, this article summarizes the types, incidence, prevention, management, and pharmaceutical care of common as well as rare but important toxicities of ibrutinib. It is expected to provide evidence-based recommendations and minimize side effects.

Key words: ibrutinib, adverse drug reaction, pharmaceutical care, evidence-based

中图分类号:

李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.

LI Yanming, ZHAO Zhigang. Evidence-based ibrutinib-related adverse reactions and pharmaceutical care[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 807-811.

参考文献

[1] SIVINA M, KREITMAN RJ, ARONS E, et al.The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach[J]. Br J Haematol, 2014, 166(2): 177-188.
[2] WANG J, LIU X, HONG Y, et al.Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma[J]. J Exp Clin Canc Res, 2017, 36(1): 96.
[3] SOUSSAIN C, CHOQUET S, BLONSKI M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) andthe French oculo-cerebral lymphoma (LOC) network[J]. Eur J Cancer, 2019, (8)117: 121-130.
[4] RICHARDSON PG, BENSINGER WI, HUFF CA, et al.Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results[J]. Br J Haematol, 2018, 180(6): 821-830.
[5] AL-TOUBAH T, SCHELL MJ, CIVES M, et al.A phase ii study of ibrutinib in advanced neuroendocrine neoplasms[J]. Neuroend-ocrinology, 2020, 110(5): 377-383.
[6] HOU K, YU Z, JIA Y, et al.Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis[J]. Crit Rev Oncol Hematol, 2020, 152(8): 103010.
[7] STEPHENS DM, BYRD JC.How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia[J]. Blood, 2019, 133(12): 1298-1307.
[8] ALLOUCHERY M, TOMOWIAK C, GUIDEZ S, et al.Patterns of use and safety of ibrutinib in real-life practice[J]. Br J Clin Pharmacol, 2021, 87(3): 895-904.
[9] BYRD JC, FURMAN RR, COUTRE SE, et al.Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib[J]. Blood, 2015, 125(16): 2497-2506.
[10] National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5[R/OL].(2017-11-27)[2020-06-30]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
[11] BROWN JR, MOSLEHI J, EWER MS, et al.Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis[J]. Br J Haematol, 2019, 184(4): 558-569.
[12] MOCK J, KUNK PR, PALKIMAS S, et al.Risk of major bleeding with ibrutinib[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(11):755-761.
[13] CALDEIRA D, ALVES D, COSTA J, et al.Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis[J]. PLoS One, 2019, 14(2): e0211228.
[14] BROWN JR, MOSLEHI J, O'BRIEN S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials[J]. Haematologica,2017, 102(10): 1796-1805.
[15] BYRD JC, FURMAN RR, COUTRE SE, et al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2013, 369(1): 32-42.
[16] BARR PM, ROBAK T, OWEN C, et al.Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2[J]. Haematologica, 2018, 103(9): 1502-1510.
[17] DICKERSON T, WICZER T, WALLER A, et al.Hypertension and incident cardiovascular events following ibrutinib initiation[J]. Blood, 2019, 134(22): 1919-1928.
[18] TILLMAN BF, PAUFF JM, SATYANARAYANA G, et al.Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies[J]. Eur J Haematol, 2018, 100(4): 325-334.
[19] VARUGHESE T, TAUR Y, COHEN N, et al.Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer[J].Clin Infect Dis, 2018, 67(5): 687-692.
[20] ROGERS KA, LUAY M, ZHAO Q, et al.Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center[J]. Blood, 2017, 130(S1): 830.
[21] LIU MY, CAI J, YAO Y, et al.Literature analysis of invasive fungal infections induced by ibrutinib[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2020, 29(9): 647-651.
[22] BALL S, DAS A, VUTTHIKRAIVIT W, et al.Risk of infection associated with ibrutinib in patients with b-cell malignancies: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(2): 87-97.
[23] ZHOU Y, LU H, YANG M, et al.Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized trials[J]. Medicine, 2019, 98(33): e16915.
[24] BROWN JR, HILLMEN P, O' BRIEN S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL[J]. Leukemia, 2018, 32(1): 83-91.
[25] PAYDAS S.Management of adverse effects/toxicity of ibrutinib[J].Crit Rev Oncol Hematol, 2019, 136: 56-63.
[26] SIBAUD V, BEYLOT-BARRY M, PROTIN C, et al.Dermatological toxicities of bruton's tyrosine kinase inhibitors[J]. American Journal of Clinical Dermatology, 2020 21(6): 799-812.
[27] IBERRI DJ, KWONG BY, STEVENS LA, et al.Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management[J]. Br J Haematol, 2018, 180(1): 164-166.
[28] STEWART J, BAYERS S, VANDERGRIFF T.Self-limiting ibrutinib-induced neutrophilic panniculitis[J]. Am J Dermato-pathol, 2018, 40(2): e28-e29.
[29] BITAR C, FAROOQUI MZ, VALDEZ J, et al.Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia[J]. JAMA Dermatol, 2016, 152(6): 698-701.
[30] BYRD JC, BROWN JR, O'BRIEN S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia[J]. N Engl J Med, 2014, 371(3): 213-223.
[31] BURGER JA, TEDESCHI A, BARR PM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015, 373(25): 2425-2437.
[32] RHODES JM, LORE VA 3rd, MATO AR, et al. Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(7): 438-444.
[33] COUTRE SE, BYRD JC, HILLMEN P, et al.Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies[J]. Blood Adv, 2019, 3(12): 1799-1807.
[34] PUŁA A, STAWISKI K, BRAUN M, et al. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials[J]. Leuk Lymphoma, 2018, 59(5): 1084-1094.
[35] HERMAN SE, NIEMANN CU, FAROOQUI M, et al.Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study[J]. Leukemia, 2014, 28(11): 2188-2196.
[36] ROGERS KA, RUPPERT AS, BINGMAN A, et al.Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia[J]. Leukemia, 2016, 30(2): 346-350.
[37] TAFESH ZH, COLEMAN M, FULMER C, et al.Severe hepatot-oxicity due to ibrutinib with a review of published cases[J]. Case Rep Gastroenterol, 2019, 13(2): 357-363.
[38] HERISHANU Y, KATCHMAN H, POLLIACK A.Severe hepatitis B virus reactivation related to ibrutinib monotherapy[J]. Ann Hematol, 2017, 96(4): 689-690.
[39] MOLICA S, LEVATO L, MIRABELLI R.Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature[J]. Leuk Lymphoma, 2016, 57(3): 735-737.
[40] ATKINSON BT, ELLMEIER W, WATSON SP.Tec regulates platelet activation by GPVI in the absence of Btk[J]. Blood, 2003, 102(10): 3592-3599.
[41] CHEN J, KINOSHITA T, GURURAJA T, et al.The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)[J]. European Journal of Haematology, 2018, 101(5): 604-612.
[42] MCMULLEN JR, BOEY EJ, OOI JY, et al.Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling[J]. Blood, 2014, 124(25): 3829-3830.
[43] JIANG L, LI L, RUAN Y, et al.Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium[J]. Heart Rhythm, 2019, 16(9): 1374-1382.
[44] DUBOVSKY JA, BECKWITH KA, NATARAJAN G, et al.Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes[J]. Blood, 2013, 122(15): 2539-2549.
[45] KOHRT HE, SAGIV-BARFI I, RAFIQ S, et al.Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity[J]. Blood, 2013, 122(21): 373.
[46] ZERBIT J, CHEVRET S, BERNARD S, et al.Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study[J]. Ann Hematol, 2020, 99(7): 1615-1625.
[47] SCHEERS E, LECLERCQ L, DE JONG J, et al.Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men[J]. Drug Metab Dispos. 2015, 43(2): 289-297.
[48] DE JONG J, SKEE D, MURPHY J, et al.Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants[J].Pharmacology Research & Perspectives, 2015, 3(4): 00156.
[49] TREON SP, TRIPSAS CK, MEID K, et al.Ibrutinib in previously treated Waldenström's macroglobulinemia[J]. N Engl J Med, 2015, 372(15): 1430-1440.
[50] KAPELIOS CJ, BONOU MS, DIAMANTOPOULOS P, et al.Ibrutinib-related atrial fibrillation: therapeutic challenges[J].Journal of Oncology Pharmacy Practice, 2019, 25(5): 1258-1260.
[51] LASICA M, TAM CS.Management of ibrutinib toxicities: a practical guide[J]. Curr Hematol Malig Rep, 2020, 15(3): 177-186.